Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.

Tempus AI (TEM) announced it has acquired Deep 6 AI. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate ...

In the article appearing in the AACR Journal, researchers at the Henry Ford Health Pancreatic Cancer Center, found that Black ...

We recently published a list of Top 10 Stocks Everyone Is Talking About These Days. In this article, we are going to take a ...

Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic ...

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing ... National Cancer Institute (NCI)-Designated ...

Cancer cells can hijack this signal ... Molecular profiles of patient tumors were determined from the Tempus multimodal database, through collaboration between Dr. Huang’s team, Tempus AI ...

Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector.